Best Penny Stocks to Buy? You Might Want to Add These 3 To Your Watchlist
3 penny stocks investors can't get enough of
The potential of penny stocks is largely unmatched by other stocks. This is not to say that all penny stocks have value, however the large intraday swings we see are not common in blue chips. For this reason, many swing traders and those looking for cheap stocks to buy long term prefer penny stocks to keep an eye on. The key with stocks under $ 5 is volatility.
Because it is so common for prices to shoot up and down significantly on any given day, investors can find many entry and exit points that could offer opportunities. On the other hand, investors who are not that experienced will find a lot of problems with these big price moves.
However, with proper trading training, anyone with a brokerage account can find valuable penny stocks to look at. While many penny stocks are traded on OTC or OTC markets, there are many penny stocks available from Robinhood or other brokerage firms.
Because of this, the accessibility is higher than ever. But just because a stock is below $ 5 doesn't mean it has a forward value. Rather, investors of all skill levels need to do proper research to ensure a company has solid financials and a game plan for the future.
With these factors in mind, it can be easy to create a premium watchlist for penny stocks. With all of the above in mind, here are three penny stocks that you might want to add to your watchlist.
3 Penny Stocks To Watch For Now
Zomedica Corp. (NYSE: ZOM)
We have been covering the ZOM share for months. And there are a couple of clear reasons for that. For one thing, the ZOM share has risen by more than 1,050% in the past six months. This is an overwhelming win and one that strongly indicates the volatility of Zomedica. It has a lot to do in its pipeline, however. In some context, Zomedica is a provider of diagnostic tools for use in the veterinary industry.
His primary focus is developing innovative tools to diagnose common problems in pets. This includes both cats and dogs, which are their main market. This also includes the Truforma platform, a point-of-care product for use in veterinary offices.
Last week the company announced that it would set up direct sales for the Truforma platform. This is very important as one of the most common problems facing any biotech company is sales.
“With Truforma's increasing presence in the market, we wanted to move from a dealer-based sales model to a direct sales organization. Due to anticipated changes in our current distributor that we believe have affected their ability to effectively market our products, we will expedite this transition and the establishment of a direct sales organization.
While these efforts may slow down the initial sales of Truforma, we have now taken this step to avoid disruptions for our customers. "
Zomedica CEO, Robert CohenZomedica currently employs eight sales representatives in the field. With Truforma only announcing its first commercial sale last month, the company is still in the very early stages of commercialization. With that in mind, is ZOM stock worth a look?
Jaguar Health Inc. (NASDAQ: JAGX)
If you're looking for a purer, commercial-phase biotech company, Jaguar Health might be worth checking out. The company focuses on the development of new, herbal, non-opioid and sustainably sourced prescription drugs. These drugs are used to treat gastrointestinal or gastrointestinal problems.
In addition, subsidiary Napo Pharmaceuticals is working on a similar goal. Jaguar's lead product, known as Mytesi (Crofelemer), is an FDA-cleared compound for the symptomatic relief of non-infectious diarrhea in HIV / AIDS patients receiving retroviral therapy.
In addition, Mytesi is the only oral herbal prescription drug for this treatment that has been approved under FDA Botanical Guidance. Just a few weeks ago the company announced an increased offer of 15.3 million US dollars with Ladenburg Thalmann & Co. Inc. This offering will help the company find new business opportunities without worrying about diluting its shares.
Lisa Conte, CEO of Jaguar, said, “We are very pleased to have expanded the capacity of the ATM program. While we are not currently anticipating the issuance of shares, the expanded ATM program is available to provide the company with future funding at the current market price at the time of sale, based on the time, if required.
This funding will also enable Jaguar and Napo to fund the ongoing pivotal Phase 3 study of Crofelemer for the prevention of diarrhea in adult cancer patients. Given that funding and what it will do for the company, is JAGX stock on your penny stock watchlist?
Compliant Inc. (NASDAQ: CFMS)
ConforMIS is another biotech penny stock that we've been discussing a lot over the past few months. Before we dive into the latest developments, let's talk about a quick rundown of what the company does. ConforMIS is a medical device company using its proprietary iFit Image-to-Implant technology. From this, individually adapted and individually manufactured replacement implants are made.
Replacement joints such as personalized knee and hip implants as well as single-use instruments are in the pipeline. The iTotal CR knee replacement has shown an incredibly high clinical efficacy on its own and compared to existing, commercially available implants.
Yesterday the company announced the achievement of its third milestone under its license and development agreement with Howmedica Osteonics Corp. known. As a result, it is now receiving a $ 11 million milestone payment from Howmedica's parent company, Stryker Orthopedics. The
“We are pleased to have reached the last milestone of our project with the recently granted FDA approval and to announce the successful conclusion of our joint development agreement with Stryker. Despite the global challenges of the past 12 months, the commitment of our project and support teams enabled us to reach this important milestone on time. "
President and CEO of ConforMIS, Mark AugustiThis announcement comes only about a week after the release of information about a license agreement with Paragon 28 for the use of its patents in patient-specific instruments. With all of this exciting news, it looks like ConforMIS is making great strides in the biotech industry. With this in mind, is the CFMS share worth seeing?
Midam Ventures, LLC | (305) 306-3854 | 1501 Venera Ave, Coral Gables, FL 33146 | news@pennystocks.com
Comments
Post a Comment